486 related articles for article (PubMed ID: 15867388)
1. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
2. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitors reverse taxane resistance.
Marcus AI; O'Brate AM; Buey RM; Zhou J; Thomas S; Khuri FR; Andreu JM; Díaz F; Giannakakou P
Cancer Res; 2006 Sep; 66(17):8838-46. PubMed ID: 16951201
[TBL] [Abstract][Full Text] [Related]
4. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
5. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells.
Honore S; Kamath K; Braguer D; Horwitz SB; Wilson L; Briand C; Jordan MA
Cancer Res; 2004 Jul; 64(14):4957-64. PubMed ID: 15256469
[TBL] [Abstract][Full Text] [Related]
6. The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner.
Zhou J; Vos CC; Gjyrezi A; Yoshida M; Khuri FR; Tamanoi F; Giannakakou P
J Biol Chem; 2009 Apr; 284(15):9648-55. PubMed ID: 19228685
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Kim ES; Kies MS; Fossella FV; Glisson BS; Zaknoen S; Statkevich P; Munden RF; Summey C; Pisters KM; Papadimitrakopoulou V; Tighiouart M; Rogatko A; Khuri FR
Cancer; 2005 Aug; 104(3):561-9. PubMed ID: 16028213
[TBL] [Abstract][Full Text] [Related]
8. Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6.
Zilberman Y; Ballestrem C; Carramusa L; Mazitschek R; Khochbin S; Bershadsky A
J Cell Sci; 2009 Oct; 122(Pt 19):3531-41. PubMed ID: 19737819
[TBL] [Abstract][Full Text] [Related]
9. In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
Loprevite M; Favoni RE; De Cupis A; Scolaro T; Semino C; Mazzanti P; Ardizzoni A
Oncol Rep; 2004 Feb; 11(2):407-14. PubMed ID: 14719076
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo.
Zuco V; De Cesare M; Cincinelli R; Nannei R; Pisano C; Zaffaroni N; Zunino F
PLoS One; 2011; 6(12):e29085. PubMed ID: 22194993
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
12. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Caponigro F
Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
[TBL] [Abstract][Full Text] [Related]
13. Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function.
Schafer-Hales K; Iaconelli J; Snyder JP; Prussia A; Nettles JH; El-Naggar A; Khuri FR; Giannakakou P; Marcus AI
Mol Cancer Ther; 2007 Apr; 6(4):1317-28. PubMed ID: 17431110
[TBL] [Abstract][Full Text] [Related]
14. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.
Haggarty SJ; Koeller KM; Wong JC; Grozinger CM; Schreiber SL
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4389-94. PubMed ID: 12677000
[TBL] [Abstract][Full Text] [Related]
15. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines.
Catalano MG; Poli R; Pugliese M; Fortunati N; Boccuzzi G
Endocr Relat Cancer; 2007 Sep; 14(3):839-45. PubMed ID: 17914112
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.
Dowdy SC; Jiang S; Zhou XC; Hou X; Jin F; Podratz KC; Jiang SW
Mol Cancer Ther; 2006 Nov; 5(11):2767-76. PubMed ID: 17121923
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Khuri FR; Glisson BS; Kim ES; Statkevich P; Thall PF; Meyers ML; Herbst RS; Munden RF; Tendler C; Zhu Y; Bangert S; Thompson E; Lu C; Wang XM; Shin DM; Kies MS; Papadimitrakopoulou V; Fossella FV; Kirschmeier P; Bishop WR; Hong WK
Clin Cancer Res; 2004 May; 10(9):2968-76. PubMed ID: 15131032
[TBL] [Abstract][Full Text] [Related]
19. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P
J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564
[TBL] [Abstract][Full Text] [Related]
20. HDAC6 is a microtubule-associated deacetylase.
Hubbert C; Guardiola A; Shao R; Kawaguchi Y; Ito A; Nixon A; Yoshida M; Wang XF; Yao TP
Nature; 2002 May; 417(6887):455-8. PubMed ID: 12024216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]